If CRISPR stays active too long, it could cut unintended parts of the genome. To reduce this risk, the researchers designed a self-inactivating CRISPR system. This means that CRISPR edits the gene and ...

Artificial Intelligence, or AI, has become an everyday feature of the world we live in. Internet browsers have an ‘AI mode’ and even our refrigerators and vacuum cleaners now include AI features!

9 min read |New research in a HD mouse model points to a key culprit: a small fragment called HTT1a. Lowering HTT1a levels successfully delayed disease signs in mice that model HD, perhaps shaping the ...

A small study based in Ireland asked a simple question: what does caring for someone with Huntington’s disease feel like? The answers point to isolation, stigma, and major gaps in healthcare support ...

A new collaboration between researchers at Indiana University Southeast and Bellarmine University in Kentucky, both in the USA, aimed to investigate what happens when a physical therapist and a music ...

Scientists used cells from a person with Huntington’s disease (HD) to test whether lowering the levels of DNA repair genes can slow the growth of the nefarious CAG repeat. In these human cells grown ...

Greetings from Day 2 of the CHDI HD Therapeutics Conference! HDBuzz continues to provide summaries of the exciting talks from HD scientists gathered in Palm Springs from around the world. This day’s ...

AMT-130 is a gene therapy designed to lower levels of the huntingtin protein in the brain. It uses a harmless virus package, called an adeno-associated virus (AAV), to contain microRNA – genetic ...

When caring for people affected by Huntington’s disease (HD), doctors often face major challenges due to the lack of precise tools to track how the disease progresses or to predict exactly when a ...

For individuals in the HD “grey zone” between 36-39 repeats, an understanding of when symptoms may arise and what kind of symptoms is critical. A new study sheds light on different sequence patterns ...

Skyhawk Therapeutics has announced results from a Phase 1 clinical study of its experimental huntingtin-lowering drug, SKY-0515. As with all Phase 1 studies, the main goal was to understand safety and ...